A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice
- PMID: 7773294
- DOI: 10.1038/ng0395-305
A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice
Abstract
To test the behaviour of a mutant form of p53 in the presence and absence of wild-type p53 in vivo, we mated p53-deficient mice containing a p53 null allele to transgenic mice containing multiple copies of a mutant p53 gene (Val 135). Animals hemizygous for the endogenous wild-type p53 gene with the mutant transgene exhibited accelerated tumour development and an altered tumour spectrum compared to their non-transgenic counterparts. In contrast, transgenic and non-transgenic animals nullizygous for endogenous p53 developed tumours at the same rate. Thus, the mutant Val-135 p53 allele may act in vivo in a dominant negative manner in the presence of wild-type p53 but does not display gain of function activity in the absence of wild-type p53.
Similar articles
-
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.Nature. 1992 Mar 19;356(6366):215-21. doi: 10.1038/356215a0. Nature. 1992. PMID: 1552940
-
Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss.Oncogene. 1995 May 4;10(9):1717-23. Oncogene. 1995. PMID: 7753548
-
[Generation and analyses of transgenic mice containing mutant p53 transgene].Fukuoka Igaku Zasshi. 1999 Mar;90(3):80-7. Fukuoka Igaku Zasshi. 1999. PMID: 10339928 Japanese.
-
The p53-deficient mouse: a model for basic and applied cancer studies.Semin Cancer Biol. 1996 Oct;7(5):269-78. doi: 10.1006/scbi.1996.0035. Semin Cancer Biol. 1996. PMID: 9110404 Review.
-
Transgenic mouse models for tumour-suppressor genes.J Intern Med. 1995 Sep;238(3):233-8. doi: 10.1111/j.1365-2796.1995.tb00928.x. J Intern Med. 1995. PMID: 7673852 Review.
Cited by
-
Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways.Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14849-54. doi: 10.1073/pnas.222406899. Epub 2002 Oct 28. Proc Natl Acad Sci U S A. 2002. PMID: 12403821 Free PMC article.
-
A mouse model of uterine leiomyosarcoma.Am J Pathol. 2004 Jan;164(1):325-36. doi: 10.1016/S0002-9440(10)63122-7. Am J Pathol. 2004. PMID: 14695345 Free PMC article.
-
RXR alpha deficiency confers genetic susceptibility for aortic sac, conotruncal, atrioventricular cushion, and ventricular muscle defects in mice.J Clin Invest. 1996 Sep 15;98(6):1332-43. doi: 10.1172/JCI118920. J Clin Invest. 1996. PMID: 8823298 Free PMC article.
-
Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.J Biol Chem. 2021 Jan-Jun;296:100098. doi: 10.1074/jbc.RA120.014749. Epub 2020 Nov 21. J Biol Chem. 2021. PMID: 33208462 Free PMC article.
-
Mutational processes shape the landscape of TP53 mutations in human cancer.Nat Genet. 2018 Oct;50(10):1381-1387. doi: 10.1038/s41588-018-0204-y. Epub 2018 Sep 17. Nat Genet. 2018. PMID: 30224644 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous